159 related articles for article (PubMed ID: 6222901)
1. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
2. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
4. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
5. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
6. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
7. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
8. Low-dose aminoglutethimide in treatment of advanced breast cancer.
Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
[TBL] [Abstract][Full Text] [Related]
9. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
10. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
11. Aminoglutethimide in the treatment of advanced breast cancer.
Stuart-Harris RC; Smith IE
Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
[No Abstract] [Full Text] [Related]
12. Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer.
Scaglia HE; Koliren L; Loruso A; Zylbersztein C; Ramos G; Díaz L; Soto E
Eur J Gynaecol Oncol; 1984; 5(3):170-9. PubMed ID: 6234171
[TBL] [Abstract][Full Text] [Related]
13. Role of aminoglutethimide in male breast cancer.
Harris AL; Dowsett M; Stuart-Harris R; Smith IE
Br J Cancer; 1986 Oct; 54(4):657-60. PubMed ID: 3778807
[TBL] [Abstract][Full Text] [Related]
14. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.
Lønning PE; Kvinnsland S; Thorsen T; Ueland PM
Clin Pharmacokinet; 1987 Dec; 13(6):393-406. PubMed ID: 3436111
[TBL] [Abstract][Full Text] [Related]
15. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
[TBL] [Abstract][Full Text] [Related]
16. Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1980 Sep; 51(3):462-5. PubMed ID: 6447707
[No Abstract] [Full Text] [Related]
17. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
Coombes RC; Chilvers C; Dowsett M; Gazet JC; Ford HT; Bettelheim R; Gordon C; Smith IE; Zava D; Powles TJ
Cancer Res; 1982 Aug; 42(8 Suppl):3415s-3419s. PubMed ID: 6211228
[TBL] [Abstract][Full Text] [Related]
19. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Dowsett M; Lal A; Smith IE; Jeffcoate SL
Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
[TBL] [Abstract][Full Text] [Related]
20. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
